drugset / Trial / NCT05947643

Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)

NCT05947643

Phase 2 Completed 77 enrolled Washington University School of Medicine
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this Phase II trial is to test the effectiveness of intranasal theophylline irrigations for the treatment of COVID-19 related smell dysfunction. The investigators will compare the effect of theophylline nasal rinses versus placebo nasal rinses on smell symptoms. Participants will be asked to rinse their nose with a medication or placebo capsule dissolved in saltwater twice daily for 12 weeks and fill out surveys about smell before, during, and at the end of treatment. This study will also be used to describe adverse effects related to intranasal theophylline irrigation.

Timeline

Start
2022-11-22
Primary completion
2025-04-24
Completion
2025-08-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Theophylline Small molecule 400 mg Intranasal

Indications